Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.69 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496416 | 0.90 | ACE (0.56) | ACEACE2LTA4H | |
| SCHEMBL683834 | 0.86 | ACE (0.84) | ACEACE2LTA4H | |
| SCHEMBL27890164 | 0.86 | ACE (0.73) | ACEACE2LTA4H | |
| SCHEMBL27890165 | 0.86 | ACE (0.73) | ACEACE2LTA4H | |
| SCHEMBL27890166 | 0.83 | ACE (0.75) | ACE | |
| SCHEMBL17660482 | 0.83 | ACE (0.75) | ACE | |
| SCHEMBL27890161 | 0.83 | ACE (0.75) | ACE | |
| SCHEMBL683471 | 0.83 | ACE (0.79) | ACEACE2LTA4H | |
| SCHEMBL7328861 | 0.83 | ACE (0.72) | ACEACE2LTA4HOPRK1 | |
| SCHEMBL31621499 | 0.83 | ACE (0.64) | ACEACE2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770621-B2 | GLYCOPEPTIDE WITH TWO OR MORE CARBOXY GROUPS AT THE C-TERMINUS, NOT INCLUDING SPECIFIED TEICOPLANINS; TREATING BACTERIAL DISEASES | THERAVANCE, INC. | 2004-08-03 | — | — | US | claimed |
| US-20020055464-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2002-05-09 | — | — | US | claimed |
| WO-2001083520-A2 | POLYACID GLYCOPEPTIDE DERIVATIVES | THERAVANCE,INC (US) | 2001-11-08 | — | — | WO | claimed |
| US-7244705-B2 | Polyacid glycopeptide derivatives | THERAVANCE, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20060194716-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-08-31 | — | — | US | disclosed |
| US-7074760-B2 | Polyacid glycopeptide derivatives | THERAVANCE, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050164919-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-07-28 | — | — | US | disclosed |
| US-6906031-B2 | Polyacid glycopeptide derivatives | THERAVANCE, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040229775-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-11-18 | — | — | US | disclosed |
| US-6770621-B2 | GLYCOPEPTIDE WITH TWO OR MORE CARBOXY GROUPS AT THE C-TERMINUS, NOT INCLUDING SPECIFIED TEICOPLANINS; TREATING BACTERIAL DISEASES | THERAVANCE, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20020055464-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2002-05-09 | — | — | US | disclosed |
| WO-2001083520-A2 | POLYACID GLYCOPEPTIDE DERIVATIVES | THERAVANCE,INC (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055464-A1 | Polyacid glycopeptide derivatives | B3GAT3, GYPA, MGAT3 | ACE 1761/4885ACE2 612/4885LTA4H 2497/4885 |
| US-20040229775-A1 | Polyacid glycopeptide derivatives | B3GAT3, GYPA, MGAT3 | ACE 1761/4885ACE2 612/4885LTA4H 2497/4885 |
| US-20050164919-A1 | Polyacid glycopeptide derivatives | B3GAT3, NGLY1, DNPEP | ACE 2005/4885ACE2 1250/4885LTA4H 876/4885 |
| US-20060194716-A1 | Polyacid glycopeptide derivatives | B3GAT3, NGLY1, DNPEP | ACE 2005/4885ACE2 1250/4885LTA4H 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.